Lenvatinib (mesylate)

Lenvatinib (mesylate)

CAT N°: 29832
Price:

From 129.00 109.65

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively).{32663,32664} It also inhibits the related kinases VEGFR1, FGFR1, PDGFR?, PDGFR? and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively).{32663} Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

We also advise you